Marta Novais
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marta Novais has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jeffery W. Kelly
Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA
6 shared publications Teresa Coelho
Unidade Corino de Andrade, Centro Hospitalar do Porto, 4099-001 Porto, Portugal
4 shared publicationsCecília Monteiro
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037
3 shared publications- Evan T. Powers
Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA
2 shared publications - Jaleh Mesgarzadeh
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
2 shared publications - Raquel Seruca
Universidade do Porto
2 shared publications
Latest Publications
- 17 February 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (9)
A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction
Significance: Treating the transthyretin (TTR) amyloidoses early maximizes clinical response. Soluble nonnative protein oligomers are cytotoxic in cultured cell lines, in primary cells, and in animal models. Here we report an immunoassay for quantifying nonnative, oligomeric TTR (NNTTR) levels in human V30M TTR polyneuropathy plasma ( n = 81). High NNTTR pretreatment levels are significant for predicting which patients are less likely to respond to tafamidis ( P = 0.0025). The extent of NNTTR decrease does not differ between the tafamidis responders and nonresponders, suggesting that very high pretreatment NNTTR levels could reflect pathogenic processes that might not be ameliorated by solely reducing the amount of amyloidogenic substrate. Liver transplantation, as well as tafamidis and patisiran treatment, all lower NNTTR levels substantially.
- 17 February 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (9)
A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction
Significance: Treating the transthyretin (TTR) amyloidoses early maximizes clinical response. Soluble nonnative protein oligomers are cytotoxic in cultured cell lines, in primary cells, and in animal models. Here we report an immunoassay for quantifying nonnative, oligomeric TTR (NNTTR) levels in human V30M TTR polyneuropathy plasma ( n = 81). High NNTTR pretreatment levels are significant for predicting which patients are less likely to respond to tafamidis ( P = 0.0025). The extent of NNTTR decrease does not differ between the tafamidis responders and nonresponders, suggesting that very high pretreatment NNTTR levels could reflect pathogenic processes that might not be ameliorated by solely reducing the amount of amyloidogenic substrate. Liver transplantation, as well as tafamidis and patisiran treatment, all lower NNTTR levels substantially.
- Open Access
- 20 June 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (12)
Predictive model of response to tafamidis in hereditary ATTR polyneuropathy
BACKGROUND: The hereditary transthyretin (TTR) amyloidoses are a group of diseases for which several disease-modifying treatments are now available. Long-term effectiveness of these therapies is not yet fully known. Moreover, the existence of alternative therapies has resulted in an urgent need to identify patient characteristics that predict response to each therapy. METHODS: We carried out a retrospective cohort study of 210 patients with hereditary TTR amyloidosis treated with the kinetic stabilizer tafamidis (20 mg qd). These patients were followed for a period of 18–66 months, after which they were classified by an expert as responders, partial responders, or nonresponders. Correlations between baseline demographic and clinical characteristics, as well as plasma biomarkers and response to therapy, were investigated. RESULTS: 34% of patients exhibited an almost complete arrest of disease progression (classified by an expert as responders); 36% had a partial to complete arrest in progression of some but not all disease components (partial responders); whereas the remaining 30% continued progressing despite therapy (nonresponders). We determined that disease severity, sex, and native TTR concentration at the outset of treatment were the most relevant predictors of response to tafamidis. Plasma tafamidis concentration after 12 months of therapy was also a predictor of response for male patients. Using these variables, we built a model to predict responsiveness to tafamidis. CONCLUSION: Our study indicates long-term effectiveness for tafamidis, a kinetic stabilizer approved for the treatment of hereditary TTR amyloidosis. Moreover, we created a predictive model that can be potentially used in the clinical setting to inform patients and clinicians in their therapeutic decisions.
- 20 June 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (12)
Open AccessPredictive model of response to tafamidis in hereditary ATTR polyneuropathy
BACKGROUND: The hereditary transthyretin (TTR) amyloidoses are a group of diseases for which several disease-modifying treatments are now available. Long-term effectiveness of these therapies is not yet fully known. Moreover, the existence of alternative therapies has resulted in an urgent need to identify patient characteristics that predict response to each therapy. METHODS: We carried out a retrospective cohort study of 210 patients with hereditary TTR amyloidosis treated with the kinetic stabilizer tafamidis (20 mg qd). These patients were followed for a period of 18–66 months, after which they were classified by an expert as responders, partial responders, or nonresponders. Correlations between baseline demographic and clinical characteristics, as well as plasma biomarkers and response to therapy, were investigated. RESULTS: 34% of patients exhibited an almost complete arrest of disease progression (classified by an expert as responders); 36% had a partial to complete arrest in progression of some but not all disease components (partial responders); whereas the remaining 30% continued progressing despite therapy (nonresponders). We determined that disease severity, sex, and native TTR concentration at the outset of treatment were the most relevant predictors of response to tafamidis. Plasma tafamidis concentration after 12 months of therapy was also a predictor of response for male patients. Using these variables, we built a model to predict responsiveness to tafamidis. CONCLUSION: Our study indicates long-term effectiveness for tafamidis, a kinetic stabilizer approved for the treatment of hereditary TTR amyloidosis. Moreover, we created a predictive model that can be potentially used in the clinical setting to inform patients and clinicians in their therapeutic decisions.
- 3 April 2018
- Published by Taylor & Francis in Amyloid
- Vol. 25 (2) , 120-128
Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients
Hereditary transthyretin (TTR) amyloidosis associated with the TTRV30M (p.TTRV50M) mutation presents predominantly as an axonal polyneuropathy, with variable involvement of other organs. Serious central nervous system (CNS) and eye manifestations, including stroke, dementia, vitreous opacities and glaucoma, have been reported in untreated V30M TTR amyloidosis patients, and in these patients after treatment with liver transplantation (LT). Distinct therapies for V30M TTR amyloidosis developed during the last decade exhibit promising results in slowing the peripheral and autonomic nervous system pathology. However, the effect of these therapies on the CNS and eye manifestations of V30M TTR amyloidosis is not known. Herein, we show that in a small cohort of patients taking tafamidis orally (20 mg tafamidis meglumine daily) we could detect this small molecule in the cerebrospinal fluid (CSF) and the vitreous body. In the CSF, the ratio of TTR tetramer to tafamidis was ≈2:1, leading to a moderate kinetic stabilization of TTR in the CSF of these patients. Our data suggest that tafamidis can cross the CSF–blood and eye–blood barriers. Future studies comparing CNS and eye manifestations in patients treated with LT, kinetic stabilizers or TTR lowering drugs are essential to understand the clinical effect of our observations.
- 3 April 2018
- Published by Taylor & Francis in Amyloid
- Vol. 25 (2) , 120-128
Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients
Hereditary transthyretin (TTR) amyloidosis associated with the TTRV30M (p.TTRV50M) mutation presents predominantly as an axonal polyneuropathy, with variable involvement of other organs. Serious central nervous system (CNS) and eye manifestations, including stroke, dementia, vitreous opacities and glaucoma, have been reported in untreated V30M TTR amyloidosis patients, and in these patients after treatment with liver transplantation (LT). Distinct therapies for V30M TTR amyloidosis developed during the last decade exhibit promising results in slowing the peripheral and autonomic nervous system pathology. However, the effect of these therapies on the CNS and eye manifestations of V30M TTR amyloidosis is not known. Herein, we show that in a small cohort of patients taking tafamidis orally (20 mg tafamidis meglumine daily) we could detect this small molecule in the cerebrospinal fluid (CSF) and the vitreous body. In the CSF, the ratio of TTR tetramer to tafamidis was ≈2:1, leading to a moderate kinetic stabilization of TTR in the CSF of these patients. Our data suggest that tafamidis can cross the CSF–blood and eye–blood barriers. Future studies comparing CNS and eye manifestations in patients treated with LT, kinetic stabilizers or TTR lowering drugs are essential to understand the clinical effect of our observations.
- 13 September 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (407)
Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
Peptide probes detect misfolded transthyretin oligomers in amyloidosis patient plasma.
- 13 September 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (407)
Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
Peptide probes detect misfolded transthyretin oligomers in amyloidosis patient plasma.
- Open Access
- 1 January 2016
- Published by Ivyspring International Publisher in Theranostics
- Vol. 6 (11) , 1792-1809
Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures
Background: Early diagnosis of familial transthyretin (TTR) amyloid diseases remains challenging because of variable disease penetrance. Currently, patients must have an amyloid positive tissue biopsy to be eligible for disease-modifying therapies. Endomyocardial biopsies are typically amyloid positive when cardiomyopathy is suspected, but this disease manifestation is generally diagnosed late. Early diagnosis is often difficult because patients exhibit apparent symptoms of polyneuropathy, but have a negative amyloid biopsy. Thus, there is a pressing need for an additional early diagnostic strategy for TTR-aggregation-associated polyneuropathy and cardiomyopathy.
- 1 January 2016
- Published by Ivyspring International Publisher in Theranostics
- Vol. 6 (11) , 1792-1809
Open AccessPeripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures
Background: Early diagnosis of familial transthyretin (TTR) amyloid diseases remains challenging because of variable disease penetrance. Currently, patients must have an amyloid positive tissue biopsy to be eligible for disease-modifying therapies. Endomyocardial biopsies are typically amyloid positive when cardiomyopathy is suspected, but this disease manifestation is generally diagnosed late. Early diagnosis is often difficult because patients exhibit apparent symptoms of polyneuropathy, but have a negative amyloid biopsy. Thus, there is a pressing need for an additional early diagnostic strategy for TTR-aggregation-associated polyneuropathy and cardiomyopathy.
- Open Access
- 12 March 2014
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 53 (12) , 1993-2006
Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange
The transthyretin (TTR) amyloidoses are a group of degenerative diseases caused by TTR aggregation, requiring rate-limiting tetramer dissociation. Kinetic stabilization of TTR, by preferential binding of a drug to the native tetramer over the dissociative transition state, dramatically slows the progression of familial amyloid polyneuropathy. An established method for quantifying the kinetic stability of recombinant TTR tetramers in buffer is subunit exchange, in which tagged TTR homotetramers are added to untagged homotetramers at equal concentrations to measure the rate at which the subunits exchange. Herein, we report a subunit exchange method for quantifying the kinetic stability of endogenous TTR in human plasma. The subunit exchange reaction is initiated by the addition of a substoichiometric quantity of FLAG-tagged TTR homotetramers to endogenous TTR in plasma. Aliquots of the subunit exchange reaction, taken as a function of time, are then added to an excess of a fluorogenic small molecule, which immediately arrests further subunit exchange. After binding, the small molecule reacts with the TTR tetramers, rendering them fluorescent and detectable in human plasma after subsequent ion exchange chromatography. The ability to report on the extent of TTR kinetic stabilization resulting from treatment with oral tafamidis is important, especially for selection of the appropriate dose for patients carrying rare mutations. This method could also serve as a surrogate biomarker for the prediction of the clinical outcome. Subunit exchange was used to quantify the stabilization of WT TTR from senile systemic amyloidosis patients currently being treated with tafamidis (20 mg orally, once daily). TTR kinetic stability correlated with the tafamidis plasma concentration.
- 12 March 2014
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 53 (12) , 1993-2006
Open AccessQuantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange
The transthyretin (TTR) amyloidoses are a group of degenerative diseases caused by TTR aggregation, requiring rate-limiting tetramer dissociation. Kinetic stabilization of TTR, by preferential binding of a drug to the native tetramer over the dissociative transition state, dramatically slows the progression of familial amyloid polyneuropathy. An established method for quantifying the kinetic stability of recombinant TTR tetramers in buffer is subunit exchange, in which tagged TTR homotetramers are added to untagged homotetramers at equal concentrations to measure the rate at which the subunits exchange. Herein, we report a subunit exchange method for quantifying the kinetic stability of endogenous TTR in human plasma. The subunit exchange reaction is initiated by the addition of a substoichiometric quantity of FLAG-tagged TTR homotetramers to endogenous TTR in plasma. Aliquots of the subunit exchange reaction, taken as a function of time, are then added to an excess of a fluorogenic small molecule, which immediately arrests further subunit exchange. After binding, the small molecule reacts with the TTR tetramers, rendering them fluorescent and detectable in human plasma after subsequent ion exchange chromatography. The ability to report on the extent of TTR kinetic stabilization resulting from treatment with oral tafamidis is important, especially for selection of the appropriate dose for patients carrying rare mutations. This method could also serve as a surrogate biomarker for the prediction of the clinical outcome. Subunit exchange was used to quantify the stabilization of WT TTR from senile systemic amyloidosis patients currently being treated with tafamidis (20 mg orally, once daily). TTR kinetic stability correlated with the tafamidis plasma concentration.
- 1 November 2007
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 33 (9) , 1061-1067
Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management
- 1 November 2007
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 33 (9) , 1061-1067
Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management
- Open Access
- 27 June 2007
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 16 (18) , 2209-2214
In vitro demonstration of intra-locus compensation using the ornithine transcarbamylase protein as model
Ornithine transcarbamylase deficiency (OTCD) is an X-linked inborn defect of metabolism of the urea cycle, which causes hyperamonemia. Mutations of the OTC gene have been recognized as the genetic cause underlying the OTC deficiency. The severity of the disease is associated with the type of mutation, leading either to neonatal onset of hyperammonemia or to a later appearance of the disease. The mutation Thr125Met is associated with neonatal hyperammonemia. Recently, the disease-causing Thr125Met mutation in humans was reported as wild-type neutral allele in chimpanzees. Further analysis confirmed the presence of Met125 fixed in chimpanzees together with Thr135, representing the only two divergent positions between human and chimpanzee OTCs. Thr125 and Thr135 were identified as ancestral mammalian combination, so the Thr135Ala substitution occurred as human-specific event, whereas the substitution of Thr125Met was characteristic of the chimpanzee linage. Only when Met125 emerges in a background with the human-specific Ala135, a highly deleterious effect is observed, suggesting among other hypotheses the existence of a compensatory effect in chimpanzee. To explore this hypothesis, we built an in vitro cell model system to study the effect of the three distinct genetic backgrounds (Ala135–Thr125; Ala135–Met125 and Thr135–Met125) on the OTC protein function. We observed that the human Thr125Met mutant is inactive, whereas the chimp OTC shows an enzymatic activity comparable with the wild-type human OTC. We concluded that the presence of a threonine at position 135 in chimps rescues the deleterious effect of the methionine at position 125, in a mechanism of intra-locus compensation.
- 27 June 2007
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 16 (18) , 2209-2214
Open AccessIn vitro demonstration of intra-locus compensation using the ornithine transcarbamylase protein as model
Ornithine transcarbamylase deficiency (OTCD) is an X-linked inborn defect of metabolism of the urea cycle, which causes hyperamonemia. Mutations of the OTC gene have been recognized as the genetic cause underlying the OTC deficiency. The severity of the disease is associated with the type of mutation, leading either to neonatal onset of hyperammonemia or to a later appearance of the disease. The mutation Thr125Met is associated with neonatal hyperammonemia. Recently, the disease-causing Thr125Met mutation in humans was reported as wild-type neutral allele in chimpanzees. Further analysis confirmed the presence of Met125 fixed in chimpanzees together with Thr135, representing the only two divergent positions between human and chimpanzee OTCs. Thr125 and Thr135 were identified as ancestral mammalian combination, so the Thr135Ala substitution occurred as human-specific event, whereas the substitution of Thr125Met was characteristic of the chimpanzee linage. Only when Met125 emerges in a background with the human-specific Ala135, a highly deleterious effect is observed, suggesting among other hypotheses the existence of a compensatory effect in chimpanzee. To explore this hypothesis, we built an in vitro cell model system to study the effect of the three distinct genetic backgrounds (Ala135–Thr125; Ala135–Met125 and Thr135–Met125) on the OTC protein function. We observed that the human Thr125Met mutant is inactive, whereas the chimp OTC shows an enzymatic activity comparable with the wild-type human OTC. We concluded that the presence of a threonine at position 135 in chimps rescues the deleterious effect of the methionine at position 125, in a mechanism of intra-locus compensation.
- 1 August 2004
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 136 (2) , 137-147
Two linked genes of Leishmania infantum encode tryparedoxins localised to cytosol and mitochondrion
- 1 August 2004
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 136 (2) , 137-147
Two linked genes of Leishmania infantum encode tryparedoxins localised to cytosol and mitochondrion